
    
      Patients who fulfill eligibility criteria will be randomized to Arm A or Arm B

        -  Treatment will be administered on an outpatient basis.

        -  Upon registration participants will be randomized to Arm A (FOLFIRINOX) or Arm B
           (Gemcitabine/nab-Paclitaxel).

        -  After completion of FOLFIRINOX or Gemcitabine/Nab-paclitaxel, all participants without
           progressive disease will proceed to radiation therapy with capecitabine .

        -  Between 2 and 4 weeks after radiation is complete, participants will proceed for
           surgical resection of pancreatic cancer
    
  